

# Brent K Hollenbeck

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9639038/publications.pdf>

Version: 2024-02-01

179  
papers

5,792  
citations

81900

39  
h-index

88630

70  
g-index

182  
all docs

182  
docs citations

182  
times ranked

5908  
citing authors

#	ARTICLE	IF	CITATIONS
1	Effects of Advanced Practice Providers on Single-specialty Surgical Practice. <i>Annals of Surgery</i> , 2023, 277, e40-e45.	4.2	8
2	Promotional Payments to Medical Oncologists and Urologists and Prescriptions for Abiraterone and Enzalutamide. <i>Urology</i> , 2022, 161, 50-58.	1.0	2
3	The changing landscape of treatment and survival for men with castration-resistant prostate cancer in the era of novel treatments.. <i>Journal of Clinical Oncology</i> , 2022, 40, 67-67.	1.6	1
4	AUTHOR REPLY. <i>Urology</i> , 2022, 161, 58.	1.0	0
5	Physician Dispensing Among Urology Practices and the Use of Abiraterone or Enzalutamide for Men With Advanced Prostate Cancer. <i>JNCI Cancer Spectrum</i> , 2022, 6, .	2.9	3
6	Risk of Metabolic and Cardiovascular Adverse Events With Abiraterone or Enzalutamide Among Men With Advanced Prostate Cancer. <i>Journal of the National Cancer Institute</i> , 2022, 114, 1127-1134.	6.3	11
7	Robotic Surgery for Bladder Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2022, , .	7.4	0
8	Survival Outcomes Associated With Cytoreductive Nephrectomy in Patients With Metastatic Clear Cell Renal Cell Carcinoma. <i>JAMA Network Open</i> , 2022, 5, e2212347.	5.9	13
9	Unpacking low-value castration practices using behavior specification to guide de-implementation in prostate cancer care.. <i>Journal of Clinical Oncology</i> , 2022, 40, e17055-e17055.	1.6	0
10	Recurrence, metastasis, and survival after radical prostatectomy in the era of advanced treatments.. <i>Journal of Clinical Oncology</i> , 2022, 40, 5090-5090.	1.6	9
11	Promotional Payments Made to Urologists by the Pharmaceutical Industry and Prescribing Patterns for Targeted Therapies. <i>Urology</i> , 2021, 148, 134-140.	1.0	1
12	Comparing Costs of Radical Versus Partial Cystectomy for Patients Diagnosed With Localized Muscle-Invasive Bladder Cancer: Understanding the Value of Surgical Care. <i>Urology</i> , 2021, 147, 127-134.	1.0	2
13	Hospitalâ€physician integration and Medicareâ€™s siteâ€based outpatient payments. <i>Health Services Research</i> , 2021, 56, 7-15.	2.0	16
14	Medicare Accountable Care Organizations and the Adoption of New Surgical Technology. <i>Journal of the American College of Surgeons</i> , 2021, 232, 138-145e2.	0.5	1
15	De novo neuroendocrine transdifferentiation in primary prostate cancerâ€™a phenotype associated with advanced clinico-pathologic features and aggressive outcome. <i>Medical Oncology</i> , 2021, 38, 26.	2.5	18
16	Factors influencing treatment of veterans with advanced prostate cancer. <i>Cancer</i> , 2021, 127, 2311-2318.	4.1	6
17	Understanding Active Surveillance for Prostate Cancer. <i>JCO Oncology Practice</i> , 2021, 17, OP.20.00929.	2.9	0
18	Intensity of endâ€ofâ€life care for dualâ€eligible beneficiaries with cancer and the impact of delivery system affiliation. <i>Cancer</i> , 2021, 127, 4628-4635.	4.1	3

#	ARTICLE	IF	CITATIONS
19	Urology Workforce Changes and Implications for Prostate Cancer Care Among Medicare Enrollees. <i>Urology</i> , 2021, 155, 77-82.	1.0	4
20	Aortic valve replacement among patients with Alzheimer's disease and related dementias. <i>Journal of the American Geriatrics Society</i> , 2021, 69, 3468-3475.	2.6	1
21	Prostate cancer clinical trial completion: The role of geography. <i>Contemporary Clinical Trials</i> , 2021, 111, 106600.	1.8	3
22	Learning from the "etail end" of de-implementation: the case of chemical castration for localized prostate cancer. <i>Implementation Science Communications</i> , 2021, 2, 124.	2.2	4
23	Resurrecting immortal-time bias in the study of readmissions. <i>Health Services Research</i> , 2020, 55, 273-276.	2.0	2
24	Mechanisms of decision-making in preoperative assessment for older adult prostate cancer patients: A qualitative study. <i>Journal of Surgical Oncology</i> , 2020, 121, 561-569.	1.7	5
25	Understanding the Costs Associated With Surgical Care Delivery in the Medicare Population. <i>Annals of Surgery</i> , 2020, 271, 23-28.	4.2	61
26	Adherence and out-of-pocket costs among Medicare beneficiaries who are prescribed oral targeted therapies for advanced prostate cancer. <i>Cancer</i> , 2020, 126, 5050-5059.	4.1	10
27	Comparison of readmission and early revision rates as a quality metric in total knee arthroplasty using the Nationwide Readmission Database. <i>Annals of Translational Medicine</i> , 2020, 8, 687-687.	1.7	5
28	Reframing Financial Incentives Around Reducing Readmission After Radical Cystectomy. <i>Urology</i> , 2020, 142, 99-105.	1.0	1
29	Dynamic readmission prediction using routine postoperative laboratory results after radical cystectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 255-261.	1.6	2
30	Urologist Practice Structure and Quality of Prostate Cancer Care. <i>Urology Practice</i> , 2020, 7, 419-424.	0.5	3
31	Financial hardship among Medicare beneficiaries prescribed oral targeted therapies for advanced prostate cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, 68-68.	1.6	0
32	Medicare Accountable Care Organizations Reduce Spending on Surgery. <i>American Journal of Accountable Care</i> , 2020, 8, 12-19.	0.1	1
33	Characterising "bounce-back" readmissions after radical cystectomy. <i>BJU International</i> , 2019, 124, 955-961.	2.5	4
34	Urologist Practice Structure and Spending for Prostate Cancer Care. <i>Urology</i> , 2019, 130, 65-71.	1.0	7
35	Association between PSA values and surveillance quality after prostate cancer surgery. <i>Cancer Medicine</i> , 2019, 8, 7903-7912.	2.8	2
36	Adoption of Abiraterone and Enzalutamide by Urologists. <i>Urology</i> , 2019, 131, 176-183.	1.0	18

#	ARTICLE	IF	CITATIONS
37	Telemedicine utilization by providers in accountable care organizations. MHealth, 2019, 5, 10-10.	1.6	3
38	Determinants of quality prostate cancer survivorship care across the primary and specialty care interface: Lessons from the Veterans Health Administration. Cancer Medicine, 2019, 8, 2686-2702.	2.8	6
39	Impact of Medicare Office Visit Payment Reform on Urologic Practices. Urology, 2019, 126, 83-88.	1.0	3
40	Spillover Effects of the Hospital Readmissions Reduction Program on Radical Cystectomy Readmissions. Urology Practice, 2019, 6, 350-356.	0.5	2
41	Episode Payments for Transcatheter and Surgical Aortic Valve Replacement. Circulation: Cardiovascular Quality and Outcomes, 2019, 12, e005781.	2.2	7
42	Systematic Review of Factors Associated with the Utilization of Radical Cystectomy for Bladder Cancer. European Urology Oncology, 2019, 2, 119-125.	5.4	16
43	Inaugural Readmission Penalties for Total Hip and Total Knee Arthroplasty Procedures Under the Hospital Readmissions Reduction Program. JAMA Network Open, 2019, 2, e1916008.	5.9	9
44	Patient and Provider Variables Associated with Systemic Treatment of Advanced Prostate Cancer. Urology Practice, 2019, 6, 234-242.	0.5	12
45	Practice-Level Adoption of Conservative Management for Prostate Cancer. Journal of Oncology Practice, 2019, 15, e863-e869.	2.5	11
46	Real-World Impact of Minimally Invasive Versus Open Radical Cystectomy on Perioperative Outcomes and Spending. Urology, 2019, 125, 86-91.	1.0	12
47	Role of Post-acute Care on Hospital Readmission After High-Risk Surgery. Journal of Surgical Research, 2019, 234, 116-122.	1.6	11
48	Characterising potential bone scan overuse amongst men treated with radical prostatectomy. BJU International, 2019, 124, 55-61.	2.5	3
49	Association Between Hospital Participation in Medicare Shared Savings Program Accountable Care Organizations and Readmission Following Major Surgery. Annals of Surgery, 2019, 269, 873-878.	4.2	23
50	Followup Care after Emergency Department Visits for Kidney Stones: A Missed Opportunity. Urology Practice, 2019, 6, 24-28.	0.5	5
51	Effects of the Medicare Modernization Act on Spending for Outpatient Surgery. Health Services Research, 2018, 53, 2858-2869.	2.0	3
52	Predictors and Cost of Readmission in Total Knee Arthroplasty. Journal of Arthroplasty, 2018, 33, 2759-2763.	3.1	42
53	Impact of Accountable Care Organizations on Diagnostic Testing for Prostate Cancer. Urology, 2018, 116, 68-75.	1.0	5
54	Intermediate Endpoints After Postprostatectomy Radiotherapy: 5-Year Distant Metastasis to Predict Overall Survival. European Urology, 2018, 74, 413-419.	1.9	29

#	ARTICLE	IF	CITATIONS
55	Emergency Department Switching and Duplicate Computed Tomography Scans in Patients With Kidney Stones. <i>Urology</i> , 2018, 114, 41-44.	1.0	5
56	The Fate of Radical Cystectomy Patients after Hospital Discharge: Understanding the Black Box of the Pre-readmission Interval. <i>European Urology Focus</i> , 2018, 4, 711-717.	3.1	13
57	Early effect of Medicare Shared Savings Program accountable care organization participation on prostate cancer care. <i>Cancer</i> , 2018, 124, 563-570.	4.1	20
58	The Comparative Effectiveness of Treatments for Ureteropelvic Junction Obstruction. <i>Urology</i> , 2018, 111, 72-77.	1.0	20
59	Urologist Practice Affiliation and Intensity-modulated Radiation Therapy for Prostate Cancer in the Elderly. <i>European Urology</i> , 2018, 73, 491-498.	1.9	27
60	Association of the Hospital Readmissions Reduction Program With Surgical Readmissions. <i>JAMA Surgery</i> , 2018, 153, 243.	4.3	45
61	The implications of baseline bone health assessment at initiation of androgen deprivation therapy for prostate cancer. <i>BJU International</i> , 2018, 121, 558-564.	2.5	16
62	De-implementation of low value castration for men with prostate cancer: protocol for a theory-based, mixed methods approach to minimizing low value androgen deprivation therapy (DeADT). <i>Implementation Science</i> , 2018, 13, 144.	6.9	9
63	Impact of Biochemical Failure After Salvage Radiation Therapy on Prostate Cancer-specific Mortality: Competition Between Age and Time to Biochemical Failure. <i>European Urology Oncology</i> , 2018, 1, 276-282.	5.4	6
64	Castration remains despite decreasing definitive treatment of localized prostate cancer in the elderly: A case for de-implementation. <i>Cancer</i> , 2018, 124, 3971-3974.	4.1	2
65	National Trends in Active Surveillance for Prostate Cancer: Validation of Medicare Claims-based Algorithms. <i>Urology</i> , 2018, 120, 96-102.	1.0	24
66	Variation in prostate cancer treatment and spending among Medicare shared savings program accountable care organizations. <i>Cancer</i> , 2018, 124, 3364-3371.	4.1	8
67	Accountable Care Organizations and Prostate Cancer Care. <i>Urology Practice</i> , 2017, 4, 454-461.	0.5	9
68	Sharp Decline In Prostate Cancer Treatment Among Men In The General Population, But Not Among Diagnosed Men. <i>Health Affairs</i> , 2017, 36, 108-115.	5.2	25
69	Anatomical patterns of recurrence following biochemical relapse after post-prostatectomy salvage radiation therapy: a multi-institutional study. <i>BJU International</i> , 2017, 120, 351-357.	2.5	10
70	Implications of Prostate Cancer Treatment in Men With Inflammatory Bowel Disease. <i>Urology</i> , 2017, 104, 131-136.	1.0	17
71	Functional Outcomes Following Nerve Sparing Prostatectomy Augmented with Seminal Vesicle Sparing Compared to Standard Nerve Sparing Prostatectomy: Results from a Randomized Controlled Trial. <i>Journal of Urology</i> , 2017, 198, 600-607.	0.4	16
72	Variation in readmission expenditures after high-risk surgery. <i>Journal of Surgical Research</i> , 2017, 213, 60-68.	1.6	14

#	ARTICLE	IF	CITATIONS
73	No Differences in Population-based Readmissions After Open and Robotic-assisted Radical Cystectomy: Implications for Post-discharge Care. <i>Urology</i> , 2017, 104, 77-83.	1.0	27
74	Variation in the Use of Open Pyeloplasty, Minimally Invasive Pyeloplasty, and Endopyelotomy for the Treatment of Ureteropelvic Junction Obstruction in Adults. <i>Journal of Endourology</i> , 2017, 31, 210-215.	2.1	7
75	Potential Implications of Shortening Length of Stay Following Radical Cystectomy in a Pre-ERAS Population. <i>Urology</i> , 2017, 102, 92-99.	1.0	14
76	Cost Analysis of Treatments for Ureteropelvic Junction Obstruction. <i>Journal of Endourology</i> , 2017, 31, 204-209.	2.1	11
77	Health Care Integration and Quality among Men with Prostate Cancer. <i>Journal of Urology</i> , 2017, 197, 55-60.	0.4	14
78	Early national dissemination of abiraterone and enzalutamide for advanced prostate cancer in Medicare Part D.. <i>Journal of Clinical Oncology</i> , 2017, 35, 35-35.	1.6	3
79	Using Analytic Morphomics to Understand Short-Term Convalescence after Radical Cystectomy. <i>Bladder Cancer</i> , 2016, 2, 235-240.	0.4	4
80	Independent surgical validation of the new prostate cancer gradeâ€œgrouping system. <i>BJU International</i> , 2016, 118, 763-769.	2.5	48
81	Standardizing the definition of adverse pathology for lower risk men undergoing radical prostatectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 415.e1-415.e6.	1.6	18
82	Factors Associated With Preventive Pharmacological Therapy Adherence Among Patients With Kidney Stones. <i>Urology</i> , 2016, 93, 45-49.	1.0	27
83	A Multi-Center International Study Assessing the Impact of Differences in Baseline Characteristics and Perioperative Care Following Radical Cystectomy. <i>Bladder Cancer</i> , 2016, 2, 251-261.	0.4	13
84	Urologist Participation in Medicare Shared Savings Program Accountable Care Organizations (ACOs). <i>Urology</i> , 2016, 90, 76-81.	1.0	19
85	Early impact of Medicare accountable care organizations on cancer surgery outcomes. <i>Cancer</i> , 2016, 122, 2739-2746.	4.1	44
86	Medication Nonadherence and Effectiveness of Preventive Pharmacological Therapy for Kidney Stones. <i>Journal of Urology</i> , 2016, 195, 648-652.	0.4	27
87	Preparing Patients and Partners for Recovery From the Side Effects of Prostate Cancer Surgery: A Group Approach. <i>Urology</i> , 2016, 88, 36-42.	1.0	26
88	Prognostic Value of Percent Gleason Grade 4 at Prostate Biopsy in Predicting Prostatectomy Pathology and Recurrence. <i>Journal of Urology</i> , 2016, 196, 405-411.	0.4	89
89	A Model to Optimize Followup Care and Reduce Hospital Readmissions after Radical Cystectomy. <i>Journal of Urology</i> , 2016, 195, 1362-1367.	0.4	26
90	Implications of evolving delivery system reforms for prostate cancer care. <i>American Journal of Managed Care</i> , 2016, 22, 569-75.	1.1	16

#	ARTICLE	IF	CITATIONS
91	Understanding the Diffusion of Ambulatory Surgery Centers. <i>Surgical Innovation</i> , 2015, 22, 257-265.	0.9	10
92	Receipt of Best Care According to Current Quality of Care Measures and Outcomes in Men with Prostate Cancer. <i>Journal of Urology</i> , 2015, 193, 500-506.	0.4	7
93	Physician Use of Sacral Neuromodulation Among Medicare Beneficiaries With Overactive Bladder and Urinary Retention. <i>Urology</i> , 2015, 86, 30-34.	1.0	9
94	Impact of tertiary Gleason pattern 5 on prostate cancer aggressiveness: Lessons from a contemporary single institution radical prostatectomy series. <i>Asian Journal of Urology</i> , 2015, 2, 53-58.	1.2	12
95	Understanding Hospital Readmission Intensity after Radical Cystectomy. <i>Journal of Urology</i> , 2015, 193, 1500-1506.	0.4	43
96	Circulating Tumor Cells as Potential Biomarkers in Bladder Cancer. <i>Journal of Urology</i> , 2015, 194, 790-798.	0.4	85
97	Statin Use and Risk of Sepsis After Percutaneous Nephrolithotomy. <i>Journal of Endourology</i> , 2015, 29, 1126-1130.	2.1	3
98	Clinicopathologic characteristics of anterior prostate cancer (APC), including correlation with previous biopsy pathology. <i>Medical Oncology</i> , 2015, 32, 249.	2.5	10
99	Ambulatory Surgery Centers and Their Intended Effects on Outpatient Surgery. <i>Health Services Research</i> , 2015, 50, 1491-1507.	2.0	46
100	Prostate Capsule Sparing versus Nerve Sparing Radical Cystectomy for Bladder Cancer: Results of a Randomized, Controlled Trial. <i>Journal of Urology</i> , 2015, 193, 64-70.	0.4	28
101	Phase II clinical trial of intravesical bacillus Calmette-Guerin (BCG) followed by sunitinib for the treatment of high-risk nonmuscle-invasive bladder cancer (NMIBC).. <i>Journal of Clinical Oncology</i> , 2015, 33, 293-293.	1.6	6
102	Prognostic significance of perineural invasion in localized prostate cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, 30-30.	1.6	0
103	Ambulatory Surgery Centers and Outpatient Urologic Surgery Among Medicare Beneficiaries. <i>Urology</i> , 2014, 84, 57-61.	1.0	21
104	Ambulatory Surgery Centers and Outpatient Procedure Use Among Medicare Beneficiaries. <i>Medical Care</i> , 2014, 52, 926-931.	2.4	68
105	Expulsive Therapy Versus Early Endoscopic Stone Removal in Patients with Acute Renal Colic: A Comparison of Indirect Costs. <i>Journal of Urology</i> , 2014, 191, 673-677.	0.4	28
106	Regional Variation in Quality of Prostate Cancer Care. <i>Journal of Urology</i> , 2014, 191, 957-963.	0.4	41
107	The Economics of Bladder Cancer: Costs and Considerations of Caring for This Disease. <i>European Urology</i> , 2014, 66, 253-262.	1.9	418
108	Variation in Use of Active Surveillance among Men Undergoing Expectant Treatment for Early Stage Prostate Cancer. <i>Journal of Urology</i> , 2014, 192, 75-81.	0.4	59

#	ARTICLE	IF	CITATIONS
109	Technology Diffusion and Prostate Cancer Quality of Care. <i>Urology</i> , 2014, 84, 1066-1072.	1.0	7
110	Availability of In-Office Laboratory Services and Use of Prostate Specific Antigen Testing. <i>Urology Practice</i> , 2014, 1, 111-116.	0.5	1
111	Underuse of 24-Hour Urine Collection Among Children With Incident Urinary Stones: A Quality-of-care Concern?. <i>Urology</i> , 2014, 84, 457-461.	1.0	16
112	Understanding the Relationship Between Tumor Size, Gland Size, and Disease Aggressiveness in Men With Prostate Cancer. <i>Urology</i> , 2014, 84, 373-379.	1.0	14
113	Comparative Effectiveness of External-Beam Radiation Approaches for Prostate Cancer. <i>European Urology</i> , 2014, 65, 162-168.	1.9	24
114	Prevalence of 24-Hour Urine Collection in High Risk Stone Formers. <i>Journal of Urology</i> , 2014, 191, 376-380.	0.4	81
115	Adherence to Performance Measures and Outcomes among Men Treated for Prostate Cancer. <i>Journal of Urology</i> , 2014, 192, 743-748.	0.4	13
116	Costs of Radical Prostatectomy for Prostate Cancer: A Systematic Review. <i>European Urology</i> , 2014, 65, 316-324.	1.9	84
117	Understanding treatment disconnect and mortality trends in renal cell carcinoma using tumor registry data.. <i>Journal of Clinical Oncology</i> , 2014, 32, 403-403.	1.6	1
118	Results from the seminal vesicle sparing prostatectomy trial.. <i>Journal of Clinical Oncology</i> , 2014, 32, 55-55.	1.6	0
119	Impact of tertiary Gleason pattern 5 on prostate cancer aggressiveness: Lessons from a contemporary single institution radical prostatectomy series.. <i>Journal of Clinical Oncology</i> , 2014, 32, 15-15.	1.6	0
120	Use of Advanced Treatment Technologies Among Men at Low Risk of Dying From Prostate Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2013, 309, 2587.	7.4	122
121	Technology Diffusion and Diagnostic Testing for Prostate Cancer. <i>Journal of Urology</i> , 2013, 190, 1715-1720.	0.4	13
122	A Systematic Review of the Volume-Outcome Relationship for Radical Prostatectomy. <i>European Urology</i> , 2013, 64, 786-798.	1.9	172
123	Certificate of Need Legislation and the Dissemination of Robotic Surgery for Prostate Cancer. <i>Journal of Urology</i> , 2013, 189, 80-85.	0.4	17
124	The Impact of Technology Diffusion on Treatment for Prostate Cancer. <i>Medical Care</i> , 2013, 51, 1076-1084.	2.4	12
125	Understanding Variation in the Quality of the Surgical Treatment of Prostate Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013, 33, 278-283.	3.8	2
126	Understanding Variation in the Quality of the Surgical Treatment of Prostate Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013, , 278-283.	3.8	3



#	ARTICLE	IF	CITATIONS
127	Growth Of High-Cost Intensity-Modulated Radiotherapy For Prostate Cancer Raises Concerns About Overuse. Health Affairs, 2012, 31, 750-759.	5.2	72
128	Certificate of Need Regulations and the Diffusion of Intensity-modulated Radiotherapy. Urology, 2012, 80, 1015-1020.	1.0	10
129	Medicare Payments for Outpatient Urological Surgery by Location of Care. Journal of Urology, 2012, 188, 2323-2327.	0.4	25
130	Editorial Comment. Urology, 2012, 79, 1178-1179.	1.0	0
131	Surgical Quality Among Medicare Beneficiaries Undergoing Outpatient Urological Surgery. Journal of Urology, 2012, 188, 1274-1278.	0.4	43
132	Population Based Trends in the Surgical Treatment of Benign Prostatic Hyperplasia. Journal of Urology, 2012, 188, 1837-1841.	0.4	32
133	Use of Ureteroscopy Before and After Expansion of Lithotripter Ownership in Michigan. Urology, 2011, 78, 1287-1291.	1.0	7
134	Identifying Better Practices for Early-stage Bladder Cancer. Medical Care, 2011, 49, 1112-1117.	2.4	7
135	Opening of Ambulatory Surgery Centers and Procedure Use in Elderly Patients. Archives of Surgery, 2011, 146, 187.	2.2	34
136	Health care reform in 2010: transforming the delivery system to improve quality of care. World Journal of Urology, 2011, 29, 85-90.	2.2	22
137	Racial differences in treatment and outcomes among patients with early stage bladder cancer. Cancer, 2010, 116, 50-56.	4.1	52
138	Understanding the variation in treatment intensity among patients with early stage bladder cancer. Cancer, 2010, 116, 3587-3594.	4.1	38
139	Delays in diagnosis and bladder cancer mortality. Cancer, 2010, 116, 5235-5242.	4.1	137
140	Physician-Ownership Of Ambulatory Surgery Centers Linked To Higher Volume Of Surgeries. Health Affairs, 2010, 29, 683-689.	5.2	106
141	Ambulatory Surgery Center Market Share and Rates of Outpatient Surgery in the Elderly. Surgical Innovation, 2010, 17, 340-345.	0.9	34
142	Robotic surgery in urologic oncology: gathering the evidence. Expert Review of Pharmacoeconomics and Outcomes Research, 2010, 10, 421-432.	1.4	25
143	Provider Treatment Intensity and Outcomes for Patients With Early-Stage Bladder Cancer. Journal of the National Cancer Institute, 2009, 101, 571-580.	6.3	81
144	Disparities in the use of ambulatory surgical centers: a cross sectional study. BMC Health Services Research, 2009, 9, 121.	2.2	24

#	ARTICLE	IF	CITATIONS
145	Urologist Ownership of Ambulatory Surgery Centers and Urinary Stone Surgery Use. Health Services Research, 2009, 44, 1370-1384.	2.0	23
146	Feasibility and safety of robot-assisted salvage prostatectomy for recurrent prostate cancer following radiation therapy. Journal of Robotic Surgery, 2008, 2, 81-83.	1.8	1
147	Effects of Laparoscopy on Surgical Discharge Practice Patterns. Urology, 2008, 71, 1029-1034.	1.0	4
148	Volume-Based Referral for Cancer Surgery: Informing the Debate. Journal of Clinical Oncology, 2007, 25, 91-96.	1.6	129
149	Response: Re: Rising Incidence of Small Renal Masses: A Need to Reassess Treatment Effect. Journal of the National Cancer Institute, 2007, 99, 570-571.	6.3	8
150	Misclassification of Hospital Volume With Surveillance, Epidemiology, and End Resultsâ€™ Medicare Data. Surgical Innovation, 2007, 14, 192-198.	0.9	28
151	Volume, Process of Care, and Operative Mortality for Cystectomy for Bladder Cancer. Urology, 2007, 69, 871-875.	1.0	137
152	Measuring Convalescence After Laparoscopic Surgery. Urology, 2007, 69, 1025-1029.	1.0	8
153	Getting Under the Hood of the Volume-Outcome Relationship for Radical Cystectomy. Journal of Urology, 2007, 177, 2095-2099.	0.4	59
154	The Effects of Adjusting for Case Mix on Mortality and Length of Stay Following Radical Cystectomy. Journal of Urology, 2006, 176, 1363-1368.	0.4	72
155	Medical therapy to facilitate urinary stone passage: a meta-analysis. Lancet, The, 2006, 368, 1171-1179.	13.7	457
156	Laparoscopy for Renal Cell Carcinoma: Diffusion Versus Regionalization?. Journal of Urology, 2006, 176, 1102-1107.	0.4	78
157	Use of Nephrectomy at Select Medical Centersâ€™ A Case of Follow the Crowd?. Journal of Urology, 2006, 175, 670-674.	0.4	20
158	Risk factors for adverse outcomes after transurethral resection of bladder tumors. Cancer, 2006, 106, 1527-1535.	4.1	53
159	Incidence of Initial Local Therapy Among Men With Lower-Risk Prostate Cancer in the United States. Journal of the National Cancer Institute, 2006, 98, 1134-1141.	6.3	209
160	Importance of Perioperative Processes of Care for Length of Hospital Stay after Laparoscopic Surgery. Journal of Endourology, 2006, 20, 776-781.	2.1	7
161	Radical Cystectomy and Surgical Quality of Care. Journal of the National Comprehensive Cancer Network: JNCCN, 2005, 3, 37-42.	4.9	9
162	QUALITY OF CARE: PARTIAL CYSTECTOMY FOR BLADDER CANCERâ€™ A CASE OF INAPPROPRIATE USE?. Journal of Urology, 2005, 174, 1050-1054.	0.4	50

#	ARTICLE	IF	CITATIONS
163	THE REGIONALIZATION OF RADICAL CYSTECTOMY TO SPECIFIC MEDICAL CENTERS. Journal of Urology, 2005, 174, 1385-1389.	0.4	85
164	IDENTIFYING RISK FACTORS FOR POTENTIALLY AVOIDABLE COMPLICATIONS FOLLOWING RADICAL CYSTECTOMY. Journal of Urology, 2005, 174, 1231-1237.	0.4	248
165	The effects of stage divergence on survival after radical cystectomy for urothelial cancer. Urologic Oncology: Seminars and Original Investigations, 2005, 23, 77-81.	1.6	37
166	Early cystectomy for clinical stage T1 bladder cancer. Nature Reviews Urology, 2004, 1, 4-5.	1.4	6
167	Clinical Skills Acquisition for Hand-Assisted Laparoscopic Donor Nephrectomy. Journal of Urology, 2004, 171, 35-39.	0.4	41
168	Neoadjuvant hormonal therapy impairs sexual outcome among younger men who undergo external beam radiotherapy for localized prostate cancer. Urology, 2004, 63, 946-950.	1.0	19
169	Determinants of Long-Term Sexual Health Outcome After Radical Prostatectomy Measured by a Validated Instrument. Journal of Urology, 2003, 169, 1453-1457.	0.4	112
170	Identifying Patients Who are Suitable for Stentless Ureteroscopy Following Treatment of Urolithiasis. Journal of Urology, 2003, 170, 103-106.	0.4	50
171	Safety and Efficacy of Same-Session Bilateral Ureteroscopy. Journal of Endourology, 2003, 17, 881-885.	2.1	58
172	Concurrent assessment of obstructive/irritative urinary symptoms and incontinence after radical prostatectomy. Urology, 2002, 59, 389-393.	1.0	7
173	Neoadjuvant hormonal therapy and older age are associated with adverse sexual health-related quality-of-life outcome after prostate brachytherapy. Urology, 2002, 59, 480-484.	1.0	48
174	Ureteroscopic Treatment of Lower Pole Calculi: Comparison of Lithotripsy In Situ and After Displacement. Journal of Urology, 2002, 168, 43-45.	0.4	106
175	The utility of lockout valve reservoirs in preventing autoinflation in penile prostheses. International Urology and Nephrology, 2002, 34, 379-383.	1.4	14
176	COMPLICATIONS OF URETEROSCOPY: ANALYSIS OF PREDICTIVE FACTORS. Journal of Urology, 2001, 166, 538-540.	0.4	208
177	TESTICULAR HISTOPLASMOSIS. Journal of Urology, 2000, 164, 1652-1652.	0.4	11
178	Commercial Prices for Prostatectomy and Treatment among Younger, Privately Insured Men with Prostate Cancer. Urology Practice, 0, , .	0.5	0
179	Better Understanding the Timing of Androgen Deprivation (TOAD) Trial Outcomes: Impacts of Prior ADT. JNCI Cancer Spectrum, 0, , .	2.9	0